The ADAPTA Study: ADjuvant chemotherAPy After Curative Intent resecTion of Ampullary Cancer.

Ampullary adenocarcinoma (AAC) is a rare gastrointestinal cancer with varying survival rates, particularly the aggressive pancreatobiliary (PB) subtype. Adjuvant therapy benefits only PB and mixed subtype patients, while prospective studies are required for validation. A study proposes tailored adjuvant treatments (CAPOX for intestinal subtype, FOLFIRINOX for PB and mixed subtypes) based on histopathology to enhance survival, also exploring molecular sub-studies for deeper insights.

NCT Number	NCT06068023
Lead Sponsor	Fondazione Poliambulanza Istituto Ospedaliero Collaborators: Associazione Italiana per la Ricerca sul Cancro
Conditions	Ampullary Adenocarcinoma
Enrollment	400 participants
Start Date	2023-07-01
Primary Completion	2028-07-01 (estimated)
Study Completion	2029-07-01 (estimated)
Updated on ClinicalTrials.gov	2023-10-05